Selected article for: "Influenza test and rapid test"
Author: Duval, Xavier; van der Werf, Sylvie; Blanchon, Thierry; Mosnier, Anne; Bouscambert-Duchamp, Maude; Tibi, Annick; Enouf, Vincent; Charlois-Ou, Cécile; Vincent, Corine; Andreoletti, Laurent; Tubach, Florence; Lina, Bruno; Mentré, France; Leport, Catherine
Title: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
  • Document date: 2010_11_2
    • ID: 19sejitq_22
    Snippet: Primary endpoint. In the ITT analysis, considering the 541 enrolled patients with positive influenza A rapid test, the proportion of patients with a RT-PCR,200 cgeq/ml on day 2 of treatment was 52.6% in the oseltamivir-zanamivir arm, 62.5% in the oseltamivir monotherapy arm (p = 0. Table 2 ). The same trends were observed in the 382 fully compliant influenza A-infected patients (Table S3) , and in the 395 patients with H3N2 infection with proport.....
    Document: Primary endpoint. In the ITT analysis, considering the 541 enrolled patients with positive influenza A rapid test, the proportion of patients with a RT-PCR,200 cgeq/ml on day 2 of treatment was 52.6% in the oseltamivir-zanamivir arm, 62.5% in the oseltamivir monotherapy arm (p = 0. Table 2 ). The same trends were observed in the 382 fully compliant influenza A-infected patients (Table S3) , and in the 395 patients with H3N2 infection with proportions of 42.4% in the oseltamivir-zanamivir arm, 58.6% in the oseltamivir monotherapy arm, and 30.3% in the zanamivir monotherapy arm.

    Search related documents:
    Co phrase search for related documents
    • cgeq ml and oseltamivir monotherapy arm: 1
    • cgeq ml and oseltamivir zanamivir arm: 1, 2
    • cgeq ml and positive influenza: 1
    • cgeq ml and primary endpoint: 1, 2
    • cgeq ml and rapid test: 1
    • cgeq ml and RT cgeq ml: 1, 2
    • cgeq ml and zanamivir monotherapy arm: 1
    • enrol patient and rapid test: 1
    • ITT analysis and primary endpoint: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • monotherapy arm and oseltamivir monotherapy arm: 1
    • monotherapy arm and oseltamivir zanamivir arm: 1
    • monotherapy arm and primary endpoint: 1, 2
    • monotherapy arm and RT cgeq ml: 1
    • monotherapy arm and zanamivir monotherapy arm: 1
    • oseltamivir monotherapy arm and RT cgeq ml: 1
    • oseltamivir monotherapy arm and zanamivir monotherapy arm: 1
    • oseltamivir zanamivir arm and RT cgeq ml: 1
    • oseltamivir zanamivir arm and zanamivir monotherapy arm: 1
    • positive influenza and primary endpoint: 1, 2, 3